An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris

Linda Stein Gold; Sunhil Dhawan; Jonathan Weiss; Zoe Diana Draelos; Herman Ellman; Iain Stuart

doi:10.25251/skin.3.supp.1

Linda Stein Gold

Henry Ford Health System

Sunhil Dhawan

Center for Dermatology Clinical Research, Inc

Jonathan Weiss

Gwinnett Dermatology

Zoe Diana Draelos

Dermatology Consulting Services

Herman Ellman

Foamix Pharmaceuticals, Inc.

Iain Stuart

Foamix Pharmaceuticals, Inc.

Keywords

acne, minocycline

Abstract

Abstract not available.

References

1. Biswal I, Gaind R, Kumar N, et al. In vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris. J Infect Dev Ctries. 2016;10(10):1140-1145.

2. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderateto-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80(1):168-177.

3. Raoof J, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2019; Jun 1 [Epub ahead of print].

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.1

How to Cite

Gold, L. S., Dhawan, S., Weiss, J., Draelos, Z. D., Ellman, H., & Stuart, I. (2019). An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris. SKIN The Journal of Cutaneous Medicine, 3, S1. https://doi.org/10.25251/skin.3.supp.1

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Acne & Rosacea

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Linda Stein Gold, Hilary Baldwin, Fran Cook-Bolden, Lawrence Green, Glynis Ablon, Neil Sadick, Jonathan Weiss, Eric Guenin, Efficacy and Safety of Tazarotene 0.045% Lotion in Female Patients with Moderate-to-Severe Acne: Post Hoc Analysis by Age , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Linda Stein Gold, James Q Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
James Del Rosso, Linda Stein Gold, Sandra Marchese Johnson, Maria Jose Rueda, Hilary Baldwin, Edward L Lain, Megan Landis, Marta Rendon, Emil Tanghetti, Jonathan Weiss, Efficacy and Saftey of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Subjects with Severe Inflammatory Acne (Non-Nodulocystic) that are Candidates for Oral Isotretinoin , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, David M Pariser, Marci Levy, Eric Guenin, Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
James Q Del Rosso, Linda Stein Gold, Zoe Draelos, Tooraj Joseph Raoof, Deidre Hooper, Iain Stuart, A Prospective, Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination Of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Joseph Raoof, Deirdre Hooper, Angela Moore, Martin Zaiac, Tory Sullivan, Leon Kircik, Edward Lain, Jasmina Jankivevic, Iain Stuart, FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, Sunil Dhawan, Jonathan Weiss, Zoe D Draelos, Herman Ellman, The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Johan Selmer, Birgitte Vestbjerg, Morten Pr?stegaard, Linda Stein Gold, Phase 3 Trial Demonstrates that MC2-01 Cream has Improved Treatment Efficacy Compared to Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in Patients with Mild to Moderate Psoriasis Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Linda Stein Gold, Sunil Dhawan, Jonathan Weiss, Zoe D Draelos, Herman Ellman, The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

<< < 1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)